by no means an expert, however, the difference between an implantable device (and being a replacement heart valve, and therefore vital for survival) and a drug that can be stopped is one factor that may drive the amount of evidence required, and, having a performance level to be achieved (XX% better improvement), there will likely be a complicated calculation that will determine the necessary sample size for the trial.
Just a relatively uneducated opinion - not advice.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.03 |
Change
0.010(0.17%) |
Mkt cap ! $93.45M | |||
| Open | High | Low | Value | Volume |
| $6.00 | $6.16 | $5.80 | $52.24K | 8.792K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 857 | $5.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.45 | 1000 | 1 |
View Market Depth
| Last trade - 15.36pm 20/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |